PREGNANCY ASSOCIATED BREAST CANCER

IVA ANDRAŠEK1, ILIJA ALVIR2 and LIDIJA BEKETIĆ-OREŠKOVIĆ1,3

1Division of Radiotherapy and Internal Medicine Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia; 2Department of Gynecologic Oncology Surgery, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia; 3Department of Clinical Oncology, School of Medicine, University of Zagreb, Zagreb, Croatia

Summary

Pregnancy-associated breast cancer is a difficult psychosocial and health problem for the patient, demanding an individual multidisciplinary treatment approach. Due to the need for aggressive oncological treatment with minimal adverse effects on the growing fetus, numerous studies are carried out to find an optimal protocol, concerning the interest of both the mother and the child. Due to the physiological changes in the breasts in pregnancy, the diagnosis of breast cancer can be delayed and therefore patients have often higher clinical stage of the disease at initial presentation comparing to non-pregnant patients. Pregnancy termination due to breast cancer diagnosis had no effect on the prognosis of the patient, and long-term studies did not find a higher incidence of malignant disease in children who were exposed to chemotherapy in utero compared to the general population. Although prognosis data of those patients is controversial, recent studies have not found a worse outcome compared to breast cancer unrelated to pregnancy.

KEY WORDS: pregnancy, breast cancer, therapy, prognosis

INTRODUCTION

Pregnancy-associated breast cancer (PABC) is defined as breast cancer diagnosed during pregnancy or in the first postpartum year.
cal aspects of care that need to be considered to deliver the best treatment plan for both the mother and the child.

**Epidemiology**

Breast cancer is one of the most common cancers diagnosed in pregnancy with the frequency approaching one in 3000 pregnancies (1). In women under the age of 30, up to 20 percent of breast cancers are pregnancy-associated, but only 5 percent of breast cancers diagnosed in women younger than 50 are pregnancy related (2). Given that more women are delaying childbirth into their thirties and forties, the incidence of pregnancy-related breast cancer is expected to rise.

There is evidence suggesting a transient increase in breast cancer during the first 3–4 years following pregnancy. A Norwegian population-based study showed a short-term increase in breast cancer after full-term pregnancy, with a peak 3–4 years after the delivery (3).

Carriers of the BRCA1 and BRCA2 mutations have an increased risk of developing breast cancer in pregnancy, in fact, they are significantly more likely to develop breast cancer by the age of 40 than nulliparous carriers, with each pregnancy increasing the risk (4).

**Diagnosis**

Breast cancer in pregnant patients is usually presented as a palpable mass (5). Most patients present with a painless palpable mass or breast skin thickening during breast feeding (6). Considering that, the first obstetrical exam during pregnancy should include a thorough breast exam with encouragement of self-examinations throughout the entire pregnancy and after delivery. Pregnancy-induced breast changes, such as enlargement, are thought to be some of the reasons of the delay of the diagnosis, and perhaps a poorer outcome. In pregnancy, ultrasonography is a more suitable diagnostic procedure than mammography and can help distinguish cystic and solid breast masses. If a biopsy is indicated by ultrasonography, further mammography must be performed to identify the range of lesions, including microcalcifications. Mammograms can be performed with the use of proper abdominal shielding. Reported sensitivity of mammography ranges from 63-78%, owing to increased water content in the pregnant breast and loss of contrasting fat (7). The finding of a breast mass usually necessitates a biopsy or fine needle aspiration. It is necessary to inform the pathologist of the patient pregnancy because pregnant breast tissue is rapidly dividing and can be confused with rapidly dividing cancer cells.

Most studies have found that there are no major differences in the histology of breast cancer of pregnant and non-pregnant women (8). In 2012, Azim et al. published a case control study which included 65 patients diagnosed with breast cancer during pregnancy. They did not observe any significant histological differences between pregnant and non-pregnant patients (9).

**Treatment options**

Current National Comprehensive Cancer Network guidelines recommend pregnancy termination upon diagnosis of breast cancer in the first trimester of pregnancy. If the decision is continuation of pregnancy, the surgical procedure - mastectomy with axillary dissection is the primary recommendation during the first trimester (10).

Depending on the pathohistological results, adjuvant chemotherapy should be administered after the end of the first trimester. Most regimens use combinations of doxorubicin, cyclophosphamide and fluorouracil. The use of weekly paclitaxel is considered acceptable if indicated by disease status. Selection of both local and systemic therapies are similar to those in non-pregnancy related breast cancer, however the timing differs. Adjuvant radiation therapy as well as hormone therapy should be reserved for the postpartum period, and chemotherapy should not be administered before the second trimester. The use of blue dye is contraindicated during surgical approaches in pregnancy, radiolabeled sulfur colloid appears to be safer for sentinel node biopsy (10).

If breast cancer is diagnosed during the second trimester or beginning of the third trimester, and the patient is a candidate, neoadjuvant chemotherapeutic approach to treatment is also an option, followed by surgery and postpartum radiation and endocrine therapy, depending on the indication (10).

Mastectomy or breast-conserving surgery with axillary staging is the recommended option for tumors diagnosed in the late third trimester,
with adjuvant chemotherapy, postpartum radiation and endocrine therapy, depending on the pathohistological results, (10).

Data suggest that one third of pregnant breast cancer patient have Her-2 positive disease (11). However, one study has shown that application of trastuzumab during pregnancy increases the risk of oligohydramnios and anhydramnios and should not be recommended until postpartum (12). A recently published case report showed fetal growth retardation, oligohydramnios and right renal agenesis in a patient who became pregnant while receiving trastuzumab and pertuzumab for metastatic breast cancer, resulting in pregnancy termination (13).

Tamoxifen is a non-steroidal estrogen with both agonist and antagonist activity. The use of tamoxifen is not recommended during pregnancy, since tamoxifen and its metabolites interact with rapidly growing and developing embryonic or fetal tissues, resulting in a relatively high frequency of severe congenital anomalies such as ambiguous genitalia (14, 15).

Although chemotherapy is considered safe after the first trimester, only few studies have investigated the long-term effects of in utero exposure. Some chemotherapeutic agents are known to cross the placental barrier such as cisplatin (16), cyclophosphamide (17), doxorubicine (18) and methotrexate (19). Methotrexate has been associated with malformations of the central nervous system, skeletal, gastrointestinal, and cardiac malformations, and even fetal death (20).

In a review of 43 pregnant women given platinum-based chemotherapy, detectable cisplatin concentrations or platinum-DNA adducts were found in neonates who had been exposed to platinum derivatives during the third trimester (21). Recent studies have shown a relationship between platinum-based chemotherapy and fetuses small for gestational age (22). The long latent period of some cancers remains a problem for accurate risk identification.

Fetal outcome

There is no evidence that early termination of pregnancy improves prognosis. The decision to terminate pregnancy is, to a large extent, a personal choice of the woman or the couple, following extensive discussions with a multidisciplinary team (23).

Since pregnancy-associated breast cancer is a relatively rare disease, only few studies have investigated short and long-term effects of in utero fetal exposure to chemotherapy. An observational study which included 447 pregnant patients, 413 of whom had early breast cancer showed that even though infants exposed to chemotherapy in utero had a lower birthweight and more complications, these differences were not clinically significant and, since none of them was exposed to chemotherapy in the first trimester, were most likely related to premature delivery. A full-term delivery seems to be of outmost importance, since preterm birth was strongly associated to adverse events (24).

A recently published study on 81 pregnant patients being treated with anthracycline-based chemotherapy for breast cancer between 1992 and 2010 found no trend to indicate a higher rate of serious medical problems in the children of these patients, who were exposed to chemotherapy in utero, than that seen in the general population. Therefore it seems reasonable to conclude that treating breast cancer during the second and third trimesters with anthracycline-based chemotherapy does not jeopardize the outcome of the developing fetus (25, 26).

Lactation is contraindicated during chemotherapy, and if milk secretion is maintained throughout chemotherapy, breastfeeding can be allowed 3–4 weeks after the last administered dose of chemotherapy, since all chemotherapeutics have been detected in breast milk. Tissue fibrosis as a result of radiotherapy may inhibit lactation on the affected side in the future (27).

Prognosis

The prognosis of breast cancer in pregnant patients remains controversial. A recent retrospective study found no significant differences in overall survival, disease-free survival or distant recurrence rates between pregnant and non-pregnant breast cancer patients. Pregnancy associated status, a primary tumor larger than 5 cm and neoadjuvant chemotherapy as the primary treatment were significantly associated with an increased risk of local relapse. Interestingly, although pregnant patients have more locally advanced tumors, they did not have a higher rate of radical surgery than the control breast cancer group. Pregnancy associated status is a strong prognostic factor of
local relapse in breast cancer, so authors recommend, when possible, radical surgery as the first treatment step (28, 29).

Conclusion

Considering the trend to postpone childbearing and the general increase in the incidence of breast cancer, the incidence of pregnancy-associated breast cancer is expected to increase. An individual multidisciplinary approach is needed for this difficult psychosocial and health problem. Treatment of pregnancy-associated breast cancer should follow the guidelines for non-pregnant patients as close as possible. Evidence suggest the safety of administration of certain chemotherapy during pregnancy. Radiotherapy, trastuzumab and antihormonal treatment are contraindicated during pregnancy. Pregnancy does not seem to worsen the prognosis of breast cancer patients. Most fetal complications are related to preterm delivery, which should therefore be avoided whenever possible.

REFERENCES


Corresponding author: Lidija Beketić-Orešković, Department of Clinical Oncology, School of Medicine, University of Zagreb and Division of Radiotherapy and Medical Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Ilica 197, 10000 Zagreb, Croatia. e-mail: lidijabeketicoreskovic@gmail.com